GH Logo

Guardant Health, Inc. (GH) 

NASDAQ
Market Cap
$3.11B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
284 of 776
Rank in Industry
16 of 42

Largest Insider Buys in Sector

GH Stock Price History Chart

GH Stock Performance

About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and …

Insider Activity of Guardant Health, Inc.

Over the last 12 months, insiders at Guardant Health, Inc. have bought $38,963 and sold $160,280 worth of Guardant Health, Inc. stock.

On average, over the past 5 years, insiders at Guardant Health, Inc. have bought $8.18M and sold $445.36M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Kalia Kumud (Chief Information Officer) — $38,963.

The last purchase of 2,187 shares for transaction amount of $38,963 was made by Kalia Kumud (Chief Information Officer) on 2024‑03‑18.

List of Insider Buy and Sell Transactions, Guardant Health, Inc.

2024-06-04Saledirector
100
<0.0001%
$27.87$2,787-6.33%
2024-03-18PurchaseChief Information Officer
2,187
0.0018%
$17.82$38,963+36.74%
2024-03-04Saledirector
100
<0.0001%
$19.05$1,905+23.04%
2023-12-04Saledirector
100
<0.0001%
$26.34$2,634-13.00%
2023-12-01SaleChief Information Officer
5,800
0.0049%
$26.37$152,954-10.02%
2023-09-12SaleChief Information Officer
2,125
0.0018%
$32.59$69,254-21.71%
2023-09-05Saledirector
100
<0.0001%
$35.01$3,501-27.58%
2023-06-15Saledirector
2,766
0.0027%
$37.55$103,863-31.14%
2023-06-09PurchaseChief Information Officer
2,981
0.0029%
$32.71$97,498-20.79%
2023-03-15PurchaseCo-Chief Executive Officer
8,600
0.0082%
$26.15$224,928-0.41%
2023-03-14PurchaseCo-Chief Executive Officer
84,452
0.0813%
$26.33$2.22M0.00%
2023-03-14PurchaseCo-Chief Executive Officer
12,750
0.0123%
$26.40$336,5640.00%
2023-03-13PurchaseCo-Chief Executive Officer
60,000
0.0581%
$25.66$1.54M+3.21%
2023-03-03SaleChief Information Officer
6,500
0.0063%
$31.92$207,466-16.18%
2022-11-15SaleChief Information Officer
3,125
0.0031%
$51.87$162,082-41.89%
2022-08-17SaleChief Information Officer
2,000
0.002%
$51.39$102,781-30.89%
2022-08-11SaleSVP, People
4,500
0.0045%
$54.32$244,441-32.94%
2022-03-10Sale
4,934
0.0048%
$58.74$289,823-18.12%
2022-02-10Saledirector
4,934
0.0049%
$73.80$364,129-33.55%
2022-01-10Saledirector
4,934
0.0045%
$86.08$424,719-45.47%

Insider Historical Profitability

<0.0001%
Kalia KumudChief Information Officer
12722
0.0103%
$25.2725<0.0001%
SOFTBANK VISION FUND (AIV M1) L.P.10 percent owner
27850460
22.6386%
$25.2710+5.91%
Eltoukhy HelmyCo-Chief Executive Officer
2049238
1.6657%
$25.27437<0.0001%
Talasaz AmirAliCo-Chief Executive Officer
1902345
1.5463%
$25.27448<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$235.93M9.3511.44M+2.74%+$6.3M<0.01
BlackRock$227.22M911.01M+1.68%+$3.76M0.01
Baillie Gifford Co$128.57M5.096.23M+0.86%+$1.1M0.1
Deep Track Capital Lp$123.78M4.96M+20%+$20.63M0.57
Cadian Capital Management LP$119.51M4.735.79M+715.88%+$104.86M4.25
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.